Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

News Conference News TCT 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

Todd Neale

September 24, 2018

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

Todd Neale

September 22, 2018

Presentation TCT 2018

IMPERIAL: A Randomized Trial of Drug-Eluting Stents for Treatment of Femoropopliteal Artery Lesions

Presenter: William A. Gray

September 22, 2018

News Conference News TCT 2016

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

L.A. McKeown

November 07, 2016

News Conference News TCT 2015

IN.PACT SFA: Benefits of DCB Persist at 2 Years

October 14, 2015

News Features TCT 2014

Thoughtful Insights at TCT: Tackling Resistant Hypertension, Long SFA Lesions, and Complex Carotid Disease

Todd Neale

October 31, 2014

Presentation TCT 2014

Case Presentation

Presenter: Sahil A. Parikh

September 17, 2014

Presentation TCT 2014

Master Class in SFA Technologies: Lining up the Data

Presenter: Robert M. Bersin, Dierk Scheinert, Roger Gammon, William A. Gray

September 13, 2014

Presentation TCT 2013

SFA and Tibioperoneal Alternatives: Tailoring Therapeutic Choices

Presenter: Thomas Zeller

October 30, 2013

Presentation TCT 2013

Stenting Is the First-line Treatment for SFA Disease!

Presenter: J. Michael Bacharach

October 27, 2013

Presentation TCT 2012

SFA Intervention: State of the Art Today and in 2020

Presenter: Gary Ansel

October 24, 2012

Presentation TCT 2012

What is the Potential Economic Impact of Antiproliferative Technologies in the SFA?

Presenter: Mark Burket

October 22, 2012

Presentation TCT 2012

Drug-Coated Balloons for SFA In-Stent Restenosis: A Simple Solution for a Tenacious Problem?

Presenter: Eugenio Stabile

October 22, 2012

Presentation TCT 2012

Development of a Bioabsorbable Scaffold for the SFA

Presenter: Richard Rapoza

October 22, 2012

Presentation TCT 2012

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Pro!

Presenter: Gary Ansel

October 22, 2012

Presentation TCT 2012

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Con!

Presenter: Lawrence Garcia

October 22, 2012

Presentation TCT 2012

Adventitial Injection for SFA Restenosis: Results of an Exploratory Study

Presenter: Christopher Owens

October 22, 2012

Presentation TCT 2012

Endovascular Therapy of Common Femoral Arterial Disease

Presenter: Philip B. Dattilo, Thomas T. Tsai, Ivan P. Casserly

January 03, 2012

News Conference News

COBRA: Postdilation with Cryoplasty Reduces Restenosis in Diabetic SFA Lesions

Jason Kahn

November 30, 2011

Advertisement

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

IMPERIAL: A Randomized Trial of Drug-Eluting Stents for Treatment of Femoropopliteal Artery Lesions

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

IN.PACT SFA: Benefits of DCB Persist at 2 Years

Thoughtful Insights at TCT: Tackling Resistant Hypertension, Long SFA Lesions, and Complex Carotid Disease

Case Presentation

Master Class in SFA Technologies: Lining up the Data

SFA and Tibioperoneal Alternatives: Tailoring Therapeutic Choices

Stenting Is the First-line Treatment for SFA Disease!

SFA Intervention: State of the Art Today and in 2020

What is the Potential Economic Impact of Antiproliferative Technologies in the SFA?

Drug-Coated Balloons for SFA In-Stent Restenosis: A Simple Solution for a Tenacious Problem?

Development of a Bioabsorbable Scaffold for the SFA

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Pro!

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Con!

Adventitial Injection for SFA Restenosis: Results of an Exploratory Study

Endovascular Therapy of Common Femoral Arterial Disease

COBRA: Postdilation with Cryoplasty Reduces Restenosis in Diabetic SFA Lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content